Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David E. Avigan, M.D.

Co-Author

This page shows the publications co-authored by David Avigan and Jacalyn Rosenblatt.
Connection Strength

4.771
  1. Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. Sci Transl Med. 2016 12 07; 8(368):368ra171.
    View in: PubMed
    Score: 0.689
  2. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res. 2013 Jul 01; 19(13):3640-8.
    View in: PubMed
    Score: 0.538
  3. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother. 2011 Jun; 34(5):409-18.
    View in: PubMed
    Score: 0.470
  4. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood. 2011 Jan 13; 117(2):393-402.
    View in: PubMed
    Score: 0.451
  5. Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28. J Immunother. 2010 Feb-Mar; 33(2):155-66.
    View in: PubMed
    Score: 0.428
  6. Immunomodulatory effects of vitamin D: implications for GVHD. Bone Marrow Transplant. 2010 Sep; 45(9):1463-8.
    View in: PubMed
    Score: 0.427
  7. Cellular immunotherapy for multiple myeloma. Best Pract Res Clin Haematol. 2008 Sep; 21(3):559-77.
    View in: PubMed
    Score: 0.388
  8. Can leukemia-derived dendritic cells generate antileukemia immunity? Expert Rev Vaccines. 2006 Aug; 5(4):467-72.
    View in: PubMed
    Score: 0.336
  9. Dendritic cell fusion vaccines for cancer immunotherapy. Expert Opin Biol Ther. 2005 May; 5(5):703-15.
    View in: PubMed
    Score: 0.308
  10. Induction of antitumor immunity ex vivo using dendritic cells transduced with fowl pox vector expressing MUC1, CEA, and a triad of costimulatory molecules (rF-PANVAC). J Immunother. 2012 Sep; 35(7):555-69.
    View in: PubMed
    Score: 0.128
  11. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother. 2013 Jan; 62(1):39-49.
    View in: PubMed
    Score: 0.126
  12. Dendritic/tumor fusion cells as cancer vaccines. Semin Oncol. 2012 Jun; 39(3):287-95.
    View in: PubMed
    Score: 0.126
  13. Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells. J Immunol. 2008 Jul 01; 181(1):808-21.
    View in: PubMed
    Score: 0.096
  14. Fusion of dendritic cells with multiple myeloma cells results in maturation and enhanced antigen presentation. Br J Haematol. 2005 Jun; 129(5):687-700.
    View in: PubMed
    Score: 0.077
  15. Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity. Cancer Discov. 2017 07; 7(7):750-765.
    View in: PubMed
    Score: 0.044
  16. Increased program cell death-1 expression on T lymphocytes of patients with progressive multifocal leukoencephalopathy. J Acquir Immune Defic Syndr. 2012 Jul 01; 60(3):244-8.
    View in: PubMed
    Score: 0.032
  17. Management of relapsed and relapsed/refractory multiple myeloma. J Natl Compr Canc Netw. 2011 Oct; 9(10):1209-16.
    View in: PubMed
    Score: 0.030
  18. MUC1-C oncoprotein suppresses reactive oxygen species-induced terminal differentiation of acute myelogenous leukemia cells. Blood. 2011 May 05; 117(18):4863-70.
    View in: PubMed
    Score: 0.029
  19. PML targeting eradicates quiescent leukaemia-initiating cells. Nature. 2008 Jun 19; 453(7198):1072-8.
    View in: PubMed
    Score: 0.024
  20. MUC1 oncoprotein regulates Bcr-Abl stability and pathogenesis in chronic myelogenous leukemia cells. Cancer Res. 2007 Dec 15; 67(24):11576-84.
    View in: PubMed
    Score: 0.023
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.